Abstracts

676 – High Baseline Prevalence and Suboptimal Control of Hypertension in the REPRIEVE Trial

Background Hypertension is one of the most common comorbidities among people living with HIV (PLHIV), and a major contributor to cardiovascular disease (CVD) in REPRIEVE, highlighting its clinical importance. Although hypertension has been described in PLHIV, its prevalence and control in a large global primary cardiovascular prevention population has not been well characterized in PLHIV.…

680 – Body Roundness Index and Incident Diabetes and Hypertension Among People With and at Risk of HIV

Background Persons living with HIV (PWH) may be pre-disposed to excessive abdominal fat accumulation, which has profound consequences for cardiometabolic incidence. Common measures for assessing weight, such as body mass index (BMI), do not account for central adiposity. The body roundness index (BRI) was proposed in the general population to encompass central adiposity via inclusion…

161 – Using Machine Learning to Optimize HIV Risk Prediction and Case Identification in Eastern Kenya

Background Despite the progress achieved in HIV case identification through universal testing, shifting to risk-based testing can enhance HIV identification. While machine learning (ML) remains underutilized, it has the potential to improve HIV risk prediction and facilitate targeted HIV testing. This study evaluates the potential of ML in enhancing case identification. Methods We analyzed retrospective…

482 – Bidirectional Relationship Between Exogenous Hormones and TDF/FTC Pharmacology in Transgender Women

Background Effective HIV prevention strategies are needed for all populations, including transgender women (TGW). TGW may access exogenous hormone therapies, including estrogens and gonadotropin releasing hormone agonists (to reduce testosterone production), to promote feminization and reduce dysphoria. Yet, reports of exogenous hormone effects on the pharmacokinetics (PK) and antiviral rectal tissue pharmacodynamics (PD) of oral…

523 – Structural and Biochemical Characterization of a Novel Cyclic Peptide Targeting HIV-1 Capsid

Background Small molecules targeting the HIV-1 capsid (CA) have been developed to target the FG-binding pocket (FG-BP). Lenacapavir (LEN) is FDA-approved both for individuals with multidrug-resistant HIV-1 infection and for pre-exposure prophylaxis. Here, we introduce a novel class of CA inhibitors based on cyclic peptides (CyPeps). CyPeps offer advantages of high oral bioavailability and structural…

248 – Multiomics Reveals Metabolic and Microbial Markers of Serious Non-AIDS Event Risk in PWH

Background Antiretroviral therapy (ART) has transformed HIV into a chronic condition with near-normal life expectancy, yet a gap remains due to inflammation-mediated comorbidities and serious non-AIDS events (SNAEs) such as cancer and cardiovascular disease that persist despite treatment. SNAE risk and mortality are particularly elevated in people with HIV (PWH) with unfavorable T-cell immunologic profiles…

570 – Extent and Impact of APOBEC3 Editing on HIV-1 Proviral DNA Drug Resistance

Background APOBEC3-mediated G-to-A hypermutation in HIV-1 proviral DNA complicates drug resistance interpretation. Its extent varies across sequences. Available tools can detect but cannot differentiate mutations driven by drug pressure from APOBEC3 editing. Thresholds and criteria for excluding hypermutated sequences are undefined, limiting interpretation and clinical decision-making.  Methods We sequenced near-full-length (nFL) HIV-1 proviral genomes from…

606 – Elevated Triglyceride and Ceramide Metabolites in MASLD Among PWH

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over one-third of people with HIV (PWH), yet underlying mechanisms and metabolic signatures remain poorly defined. Dysregulated lipid metabolism may play a key role. This study aimed to identify distinctive plasma lipid metabolite patterns in PWH with MASLD. Methods We conducted a matched case-control study of 50…

640 – Distribution of High Resolution Anoscopists in the United States

Background Anal cancer disproportionately affects people with HIV (PWH) and is preventable via ablation of high-grade dysplasia through high-resolution anoscopy (HRA). Performing HRAs requires specific training not routinely offered by any subspecialty and are often performed by infectious disease, surgery, gastroenterology and gynecology subspecialists, among others. Anal cancer screening with HRAs is now recommended by…